Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | MGAM | O43451 | 3/20 | 0.34 |
| ▸ | SI | P14410 | 3/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493553 | 0.92 | MAPT (0.48) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2856378 | 0.91 | FLT3 (0.44) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2861148 | 0.90 | KDM4E (0.40) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2858839 | 0.89 | ALDH1A1 (0.38) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2858356 | 0.89 | RAB9A (0.41) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2862952 | 0.88 | KDM4E (0.36) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2860150 | 0.88 | KDM4E (0.46) | KDM4ERAB9APOLBHSD17B10GAA | |
| SCHEMBL2865481 | 0.87 | KDM4E (0.45) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2866472 | 0.82 | ALDH1A1 (0.37) | KDM4ENPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2858279 | 0.82 | KDM4E (0.44) | KDM4EMAPTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | KDM4E 2968/4885NPC1 1079/4885RAB9A 1598/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | KDM4E 2968/4885NPC1 1079/4885RAB9A 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.